Apolipoprotein B/apolipoprotein A1 ratio and mortality among incident peritoneal dialysis patients

Lipids in Health and Disease
Xiaojiang ZhanQinkai Chen

Abstract

To investigate the association between the ratio of apolipoprotein B (apo B) / apolipoprotein A1 (apo A1) with all-cause mortality and cardiovascular events in peritoneal dialysis (PD) patients. Eight hundred and sixty incident PD patients were enrolled from November 1, 2005, to February 28, 2017, and followed until May 31, 2017. Outcomes were all-cause mortality and cardiovascular events. Associations between the apo B/apo A1 ratio with all-cause mortality and cardiovascular events were evaluated using multivariable-adjusted Cox models. Of the 860 patients, the mean age was 49.9 ± 14.5 years, 57.6% were men, and 19.3% were diabetic patients. The median apo B/apo A1 ratio was 0.65 (range: 0.22-2.24). During a median follow-up period of 27 months (interquartile range, 13 - 41 months), 202 deaths, and 145 cardiovascular events were recorded. After adjustment for age, sex, body mass index, diabetes, cardiovascular disease, systolic blood pressure, total Kt/V, estimated glomerular filtration rate, hemoglobin level, neutrophil to lymphocyte ratio and albumin, triglyceride, and cholesterol, as well as the use of lipid-lowering agents, the highest apo B/apo A1 ratio tertile was significantly associated with a hazard ratio for all-caus...Continue Reading

References

Jan 1, 1994·Blood Purification·G A Kaysen
Jan 1, 1997·The American Journal of Cardiology·A D SnidermanJ Kjekshus
Jan 21, 2006·Seminars in Dialysis·Jia Liu, Mitchell H Rosner
Feb 16, 2006·Journal of Internal Medicine·G WalldiusI Jungner
Mar 13, 2008·Diabetes, Obesity & Metabolism·M Andrikoula, I F W McDowell
Apr 25, 2009·Diabetic Medicine : a Journal of the British Diabetic Association·E M DahlénC J Ostgren
Jul 12, 2014·Journal of the American Society of Nephrology : JASN·Günther SilbernagelWinfried März
Nov 19, 2014·Journal of the American Heart Association·David C WheelerUNKNOWN EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial Investigators
Feb 26, 2016·Clinical Journal of the American Society of Nephrology : CJASN·Yuji SatoShuji Iwatsubo
Aug 28, 2016·European Heart Journal·Alberico L CatapanoUNKNOWN ESC Scientific Document Group
Jul 12, 2017·International Journal of Cardiology·Wang ZhaoShui-Ping Zhao
Sep 25, 2017·The Canadian Journal of Cardiology·Yiming M ZhuEva M Lonn

❮ Previous
Next ❯

Citations

Dec 7, 2018·International Urology and Nephrology·Neris DincerMehmet Kanbay
Feb 23, 2020·Journal of Clinical Lipidology·Zhong ZhongZhijian Li

❮ Previous
Next ❯

Methods Mentioned

BETA
dissection

Software Mentioned

SPSS

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.